Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 16/20 | 0.55 |
| ▸ | GRM5 | P41594 | 9/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29545411 | 0.92 | MAOB (0.47) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL24357848 | 0.92 | MAOB (0.47) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL6087253 | 0.89 | MAOB (0.43) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL16499631 | 0.86 | MAOB (0.53) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL13506366 | 0.81 | GRM5 (0.58) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL6265978 | 0.81 | DRD2 (0.43) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL15205858 | 0.78 | MAOB (0.39) | MAOBGRM5NPC1ALDH1A1HPGD | |
| SCHEMBL16856551 | 0.78 | STS (0.40) | MAOBALDH1A1HPGDMAOA | |
| SCHEMBL4157926 | 0.78 | MAOB (0.57) | MAOBGRM5MAOA | |
| SCHEMBL13506182 | 0.78 | MAOB (0.63) | MAOBGRM5NPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104045632-B | Antineoplastic benzodihydropyran (thiapyran) amides compound and pharmaceutically acceptable salt thereof and preparation method and application | 辽宁大学 | 2016-09-07 | — | — | CN | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| CN-104045632-A | Antitumor drugs benzodihydropyran(thiapyran)amide compounds and pharmaceutically acceptable salts, and preparation method and application thereof | UNIV LIAONING | 2014-09-17 | — | — | CN | disclosed |
| EP-2597089-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2493866-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2004092116-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092164-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| EP-1196411-B1 | BRADYKININ B1 RECEPTOR ANTAGONISTS | PHARMACOPEIA INC (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1270000-A2 | Benzoic acid substituted benzopyrans for the treatment of atherosclerosis | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| EP-1196411-A1 | BRADYKININ B1 RECEPTOR ANTAGONISTS | PHARMACOPEIA, INC. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005783-A1 | BRADYKININ B1 RECEPTOR ANTAGONISTS | PHARMACOPEIA, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | MAOB 247/4885GRM5 1126/4885NPC1 465/4885 |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, TBXA2R | MAOB 2549/4885GRM5 799/4885NPC1 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.